IP Verse

Astrazeneca Ab patent opposition analysis

Latest patents of Astrazeneca Ab opposed by its competitors

The following table provides an overview of the latest patents of Astrazeneca Ab that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3045466Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
EP4114465Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
EP2508188May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3769781Apr 19, 2023Stable Anti-Ifnar1 Formulation1
EP2785349Nov 9, 2022Combination Treatment Of Cancer1
EP3142661Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor1
EP2139494Mar 11, 2020Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate6
EP3363807Nov 13, 2019Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate1
EP2498759Aug 1, 2018Immediate Release Tablet Formulations4
EP2498758Jul 25, 2018Bilayer Tablet Formulations1

Top competitors of Astrazeneca Ab